KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Jazz Pharmaceuticals (JAZZ) Revenue (2016 - 2025)

Historic Revenue for Jazz Pharmaceuticals (JAZZ) over the last 17 years, with Q3 2025 value amounting to $1.1 billion.

  • Jazz Pharmaceuticals' Revenue rose 674.31% to $1.1 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $3.3 billion, marking a year-over-year decrease of 1835.14%. This contributed to the annual value of $4.1 billion for FY2024, which is 612.24% up from last year.
  • Latest data reveals that Jazz Pharmaceuticals reported Revenue of $1.1 billion as of Q3 2025, which was up 674.31% from $1.0 billion recorded in Q2 2025.
  • In the past 5 years, Jazz Pharmaceuticals' Revenue registered a high of $1.1 billion during Q3 2025, and its lowest value of $607.6 million during Q1 2021.
  • In the last 5 years, Jazz Pharmaceuticals' Revenue had a median value of $949.0 million in 2022 and averaged $934.9 million.
  • Per our database at Business Quant, Jazz Pharmaceuticals' Revenue skyrocketed by 3947.94% in 2021 and then soared by 102.72% in 2024.
  • Quarter analysis of 5 years shows Jazz Pharmaceuticals' Revenue stood at $896.7 million in 2021, then grew by 8.41% to $972.1 million in 2022, then grew by 4.1% to $1.0 billion in 2023, then increased by 7.53% to $1.1 billion in 2024, then grew by 3.49% to $1.1 billion in 2025.
  • Its Revenue stands at $1.1 billion for Q3 2025, versus $1.0 billion for Q2 2025 and $1.1 billion for Q4 2024.